Terbicip 250 mg Cipla
| Features | |
| Also known as | Lamisil |
| Blood pressure | Typically has no effect on blood pressure |
| Chemical name | (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine |
| Dosage (medical) | 250 mg once daily for 6 weeks (for fingernail fungus) or 12 weeks (for toenail fungus) |
| Dosage (sports) | Not applicable |
| Effects | Treats fungal infections by inhibiting the fungal squalene epoxidase, leading to a deficiency in ergosterol, an essential component of fungal cell membranes, causing cell death |
| Formula | C21H25N |
| Half-life | 200–400 hours (8.5–16.7 days) |
| Hepatotoxicity | Possible, especially with prolonged use |
| Lab Test | Liver function tests recommended before and during treatment |
| Main action | Antifungal |
| Side effects | Headache, gastrointestinal disturbances, rash, liver enzyme elevations, taste disturbances |
| Storage conditions | Store at room temperature away from moisture and heat |
| Strength | 250 mg |
| Substance class | Allylamine antifungal |
| Trade name | Lamisil, Terbinex |
| Use in sports | Not typically used in sports |
| Water Retention | None |
| Manufacturer | Cipla |